ZA200902203B - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- ZA200902203B ZA200902203B ZA200902203A ZA200902203A ZA200902203B ZA 200902203 B ZA200902203 B ZA 200902203B ZA 200902203 A ZA200902203 A ZA 200902203A ZA 200902203 A ZA200902203 A ZA 200902203A ZA 200902203 B ZA200902203 B ZA 200902203B
- Authority
- ZA
- South Africa
- Prior art keywords
- combination therapy
- therapy
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85357206P | 2006-10-23 | 2006-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200902203B true ZA200902203B (en) | 2010-08-25 |
Family
ID=39324019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200902203A ZA200902203B (en) | 2006-10-23 | 2007-10-23 | Combination therapy |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100099762A1 (fr) |
EP (1) | EP2076239A4 (fr) |
JP (1) | JP2010507572A (fr) |
AU (1) | AU2007308742A1 (fr) |
CA (1) | CA2667052A1 (fr) |
WO (1) | WO2008049157A1 (fr) |
ZA (1) | ZA200902203B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040057983A1 (en) | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
US8602961B2 (en) * | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
US20170246148A1 (en) * | 2014-09-15 | 2017-08-31 | Sound Pharmaceuticals Incorporated | Methods and Compositions for Treating Psychotic Disorders |
AU2016268340B2 (en) | 2015-05-28 | 2021-07-08 | Baylor College Of Medicine | Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels |
AU2017208123B2 (en) * | 2016-01-11 | 2022-04-21 | Egetis Therapeutics Ab | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
DE60236446D1 (de) * | 2001-09-27 | 2010-07-01 | Mental Health Res Inst Of Vict | Glutation vorlaeufer zur behandlung von neuropsychiatrisschen krankheiten |
WO2004069146A2 (fr) * | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Derives d'amide l-dopa et utilisations de ceux-ci |
US20060167068A1 (en) * | 2005-01-26 | 2006-07-27 | Seth Feuerstein | Method of treating self-injurious behavior with glutamate modulating agents |
ES2564187T3 (es) * | 2005-04-05 | 2016-03-18 | Yale University | Agentes de modulación de glutamato en el tratamiento de trastornos mentales |
KR20080028357A (ko) * | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용n-아세틸시스테인 아미드(nac 아미드) |
-
2007
- 2007-10-23 US US12/443,442 patent/US20100099762A1/en not_active Abandoned
- 2007-10-23 WO PCT/AU2007/001611 patent/WO2008049157A1/fr active Application Filing
- 2007-10-23 AU AU2007308742A patent/AU2007308742A1/en not_active Abandoned
- 2007-10-23 JP JP2009532650A patent/JP2010507572A/ja not_active Withdrawn
- 2007-10-23 EP EP07815416A patent/EP2076239A4/fr not_active Withdrawn
- 2007-10-23 CA CA002667052A patent/CA2667052A1/fr not_active Abandoned
- 2007-10-23 ZA ZA200902203A patent/ZA200902203B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007308742A1 (en) | 2008-05-02 |
EP2076239A1 (fr) | 2009-07-08 |
US20100099762A1 (en) | 2010-04-22 |
EP2076239A4 (fr) | 2010-06-30 |
CA2667052A1 (fr) | 2008-05-02 |
WO2008049157A1 (fr) | 2008-05-02 |
JP2010507572A (ja) | 2010-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL196559A0 (en) | Combination therapy | |
GB0609492D0 (en) | Therapeutic agents | |
GB0608928D0 (en) | Therapeutic agents | |
IL196556A0 (en) | Combination therapy | |
GB2436010B (en) | Therapy device | |
GB0601962D0 (en) | Therapeutic agents | |
GB0624874D0 (en) | Treatment | |
IL199992A0 (en) | Combination therapy | |
EP2054061A4 (fr) | Thérapie par combinaison | |
GB0616214D0 (en) | Therapeutic Agents | |
GB0611152D0 (en) | Therapeutic agents | |
GB0504206D0 (en) | Combination therapy | |
GB0719518D0 (en) | Therapy | |
GB0620818D0 (en) | Therapeutic agents | |
IL198026A0 (en) | Sequential combination therapy | |
GB0620059D0 (en) | Therapeutic agents | |
ZA200902203B (en) | Combination therapy | |
GB0609676D0 (en) | Therapeutic agents | |
EP2211863A4 (fr) | Polythérapie | |
GB0700284D0 (en) | Combination therapy | |
GB0604460D0 (en) | Treatment | |
GB0622195D0 (en) | Therapeutic agents | |
GB0606660D0 (en) | Targeted Therapy | |
GB0716072D0 (en) | Therapy | |
GB0700635D0 (en) | Therapy |